A new mutation of the CDH1 gene in a patient with an aggressive signet-ring cell carcinoma of the stomach

References

• Inghelmann R, Grande E, Francisci S, Verdecchia A, Micheli A, Baili P, Capocaccia R, De Angelis R. Regional estimates of stomach cancer burden in Italy. Tumori. 2007;97:367–73.
   Google Scholar
• Lauren P. The two histological main types of gastric carcinoma: diffuse and so-called intestinal-type carcinoma. an attempt at a histo-clinical classification. Acta Pathol Microbiol Scand. 1965;64:31–49. doi:10.1111/apm.1965.64.1.31.
   PubMedGoogle Scholar
• Pernot S, Voron T, Perkins G, Lagorce-Pages C, Berger A, Taieb J. Signet-ring cell carcinoma of the stomach: Impact on prognosis and specific therapeutic challenge. World J Gastroenterol. 2015;21:11428–38. doi:10.3748/wjg.v21.i40.11428.
   PubMed Web of Science ®Google Scholar
• Kim BS, Oh ST, Yook JH, Kim BS. Signet ring cell type and other histologic types: differing clinical course and prognosis in T1 gastric cancer. Surgery. 2014;155:1030–5. doi:10.1016/j.surg.2013.08.016.
   PubMed Web of Science ®Google Scholar
• Bozkaya Y, Erdem GU, Ozdemir NY, Demirci NS, Hocazade C, Yazıcı O, Zengin N. Comparison of clinicopathological and prognostic characteristics in patients with mucinous carcinoma and signet ring cell carcinoma of the stomach. Curr Med Res Opinion. 2017;33:109–16. doi:10.1080/03007995.2016.1239192.
   PubMed Web of Science ®Google Scholar
• Lu M, Yang Z, Feng Q, Yu M, Zhang Y, Mao C, Shen L, Tang J. The characteristics and prognostic value of signet ring cell histology in gastric cancer: A retrospective cohort study of 2199 consecutive patients. Medicine (Baltimore). 2016;95:e4052. doi:10.1097/MD.0000000000004052.
   PubMed Web of Science ®Google Scholar
• Piessen G, Messager M, Leteurtre E, Jean-Pierre T, Mariette C. Signet ring cell histology is an independent predictor of poor prognosis in gastric adenocarcinoma regardless of tumoral clinical presentation. Ann Surg. 2009;250:878–87. doi:10.1097/SLA.0b013e3181b21c7b.
   PubMed Web of Science ®Google Scholar
• Theuer CP, Nastanski F, Brewster WR, Butler JA, Anton-Culver H. Signet ring cell histology is associated with unique clinical features but does not affect gastric cancer survival. Am Surg. 1999;65:915–21.
   PubMed Web of Science ®Google Scholar
• Heger U, Blank S, Wiecha C, Langer R, Weichert W, Lordick F, Bruckner T, Dobritz M, Burian M, Springfeld C, et al. Is preoperative chemotherapy followed by surgery the appropriate treatment for signet ring cell containing adenocarcinomas of the esophagogastric junction and stomach? Ann Surg Oncol. 2014;21:1739–48. doi:10.1245/s10434-013-3462-z.
   PubMed Web of Science ®Google Scholar
• Zu H, Wang H, Li C, Xue Y. Clinicopathologic characteristics and prognostic value of various histological types in advanced gastric cancer. Int J Clin Exp Pathol. 2014;7:5692–700.
   PubMed Web of Science ®Google Scholar
• Kim DY, Park YK, Joo JK, Ryu SY, Kim YJ, Kim SK, Lee JH. Clinicopathological characteristics of signet ring cell carcinoma of the stomach. ANZ J Surg. 2004;74:1060–4. doi:10.1111/j.1445-1433.2004.03268.x.
   PubMed Web of Science ®Google Scholar
• Li C, Kim S, Lai JF, Hyung WJ, Choi WH, Choi SH, Noh SH. Advanced gastric carcinoma with signet ring cell histology. Oncology. 2007;72:64–8. doi:10.1159/000111096.
   PubMed Web of Science ®Google Scholar
• Taghavi S, Jayarajan SN, Davey A, Willis AI. Prognostic significance of signet ring gastric cancer. J Clin Oncol. 2012;30:3493–8. doi:10.1200/JCO.2012.42.6635.
   PubMed Web of Science ®Google Scholar
• van der Post RS, Vogelaar IP, Carneiro F, Guilford P, Huntsman D, Hoogerbrugge N, Caldas C, Schreiber KEC, Hardwick RH, Ausems MGEM, et al. Hereditary diffuse gastric cancer: updated clinical guidelines with an emphasis on germline CDH1 mutation carriers. J Med Genet. 2015;52:361–74. doi:10.1136/jmedgenet-2015-103094.
   PubMed Web of Science ®Google Scholar
• Hansford S, Kaurah P, Li-Chang H, Woo M, Senz J, Pinheiro H, Schrader KA, Schaeffer DF, Shumansky K, Zogopoulos G, et al. Hereditary diffuse gastric cancer syndrome: CDH1 mutations and beyond. JAMA Oncol. 2015;1:23–32. doi:10.1001/jamaoncol.2014.168.
   PubMed Web of Science ®Google Scholar
• Corso G, Carvalho J, Marrelli D, Vindigni C, Carvalho B, Seruca R, Roviello F, Oliveira C. Somatic mutations and deletions of the E-cadherin gene predict poor survival of patients with gastric cancer. J Clin Oncol. 2013;31:868–75. doi:10.1200/JCO.2012.44.4612.
   PubMed Web of Science ®Google Scholar
• Fitzgerald RC, Caldas C. Clinical implications of E-cadherin associated hereditary diffuse gastric cancer. Gut. 2004;53:775–8. doi:10.1136/gut.2003.022061.
   PubMed Web of Science ®Google Scholar
• Fitzgerald RC, Hardwick R, Huntsman D, Carneiro F, Guilford P, Blair V, Chung DC, Norton J, Ragunath K, Van Krieken JH, et al. Hereditary diffuse gastric cancer: updated consensus guidelines for clinical management and directions for future research. J Med Genet. 2010;47:436–44. doi:10.1136/jmg.2009.074237.
   PubMed Web of Science ®Google Scholar
• Kunz PL, Mojtahed A, Fisher GA, Ford JM, Chang DT, Balise RR, Bangs CD, Cherry AM, Pai RK. HER2 expression in gastric and gastroesophageal junction Adenocarcinoma in a US population: clinicopathologic analysis with proposed approach to HER2 Assessment. Applied Immunohistochem Mol Morphol. 2012;20:13–24. doi:10.1097/PAI.0b013e31821c821c.
   PubMedGoogle Scholar
• Bang Y-J, Van Cutsem E, Feyereislova A, Chung HC, Shen L, Sawaki A, Lordick F, Ohtsu A, Omuro Y, Satoh T, et al. Trastuzumab in combination with chemotherapy versus chemotherapy alone for treatment of HER2-positive advanced gastric or gastro-oesophageal junction cancer (ToGA): a phase 3, open-label, randomised controlled trial. Lancet. 2012;376:687–97. doi:10.1016/S0140-6736(10)61121-X.
   Web of Science ®Google Scholar
• Garziera M, Canzonieri V, Cannizzaro R, Geremia S, Caggiari L, De Zorzi M, Maiero S, Orzes E, Perin T, Zanussi S, et al. Identification and characterization of CDH1 germline variants in sporadic gastric cancer patients and in individuals at risk of gastric cancer. Plos One. 2013;8:e77035. doi:10.1371/journal.pone.0077035.
   PubMedGoogle Scholar